PN-3602

N/A

Report date: 2025/06/11 20:01:15

NME

Base Information

Drug NamePN-3602

Drug Alias NameHIF-PH2 inhibitors (CrystalGenomics/Palkion)HIF stabilizer (Palkion/CrystalGenomics)PN-3602CG-0086CG-0089

ClassificationSmall molecules

Mechanisms of ActionHypoxia-inducible factor 1 alpha inhibitorsProlyl hydroxylase domain-containing protein 2 inhibitorsErythropoietin modulators +[4]

TargetsProlyl hydroxylase domain-containing protein 2Hypoxia-inducible factor 1 alpha

Therapy Area/IndicationsIschemiaInflammationAnemia +[5]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesSouth Korea

CombinationsNo

Global Highest StatusDiscontinued (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesCrystalgenomics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesCrystalgenomics Inc Palkion Inc

Active IndicationsN/A

Inactive IndicationsIschemiaInflammationAnemia +[5]

Other Information

ATC CodeN/A